| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5843875 | Pharmacology & Therapeutics | 2016 | 8 Pages | 
Abstract
												Dendritic cells (DCs) with robust immunosuppressive activity are commonly found in the microenvironment of advanced solid tumors. These innate immune cells are generically termed regulatory DCs and include various subsets such as plasmacytoid, conventional and monocyte-derived/inflammatory populations whose normal function is subverted by tumor-derived signals. This review summarizes recent findings on the nature and function of regulatory DCs, their relationship with other myeloid subsets and unique therapeutic opportunities to abrogate malignant progression through their targeting.
											Keywords
												PEIiNOSPGE2TGFβIFN-γTMETLRUPRXBP1PD-L1IDOTDCVEGF-APD1inositol-requiring enzyme 1 alphaIRE1αMAPKSmall interfering RNAROSsiRNARNAribonucleic acidTumor immunologyindoleamine 2,3-dioxygenaseTransforming Growth Factor BetaToll-like receptorImmunosuppressionDendritic cellinducible nitric oxide synthaseendoplasmic reticulumVascular endothelial growth factorProgrammed death 1programmed death-ligand 1Tumor microenvironmentUnfolded protein responseX-box binding protein 1mitogen-activated protein kinasePERKPolyethylenimineInterferon gammaReactive oxygen species
												Related Topics
												
													Health Sciences
													Pharmacology, Toxicology and Pharmaceutical Science
													Pharmacology
												
											Authors
												Jose R. Conejo-Garcia, Melanie R. Rutkowski, Juan R. Cubillos-Ruiz, 
											